Helsinn announces launch of oral formulation of Akynzeo® in China

9 June 2020

Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

8 June 2020

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States

2 June 2020

Open Accelerator: the international program for start-ups in Life Science is back with a new Call for Solutions

26 May 2020

Linnea appoints Susanne Caspar CEO

20 May 2020

DA IBSA OLTRE 700.000 CHF PER COMBATTERE L’EMERGENZA COVID-19 DI QUESTI 245.000 CHF DONATI DAI LAVORATORI IBSA A SOSTEGNO DELLE FAMIGLIE IN DIFFICOLTÀ

13 May 2020

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

13 May 2020

IBSA DONA ALL’UFFICIO DEL MEDICO CANTONALE I TEST SIEROLOGICI PER L’INDIVIDUAZIONE DEGLI ANTICORPI AL COVID-19

8 May 2020

Farma Industria Ticino realizza una filiera produttiva locale di etanolo donando 940 litri all’EOC

23 April 2020

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis

20 April 2020